Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEDAR: Candesartan in MCI with AD biomarkers
NCT02646982Phase 2Completed
- Sponsor
- Emory University
- Start
- Jun 2016
- Primary completion
- Aug 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Candesartan with Placebo (2 arms). Primary endpoints: Number of Participants With a Hypotensive Episode at 12 months, Number of Participants With Symptoms of Hypotension at 12 months and 3 more. Started Jun 2016; status: completed.
02
Drugs
candesartan
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02646982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646982.